Phagocytex Limited builds a proprietary pCAR-M platform via engineering macrophages with AI-designed peptides in just two hours. By simply switching targeting peptides, we enable faster, safer, and personalized solid tumor therapy. Our approach overcomes CAR-T’s infiltration barriers, leveraging macrophages’ natural tumor-penetrating ability to target up to 92% of cancers.
pCAR-M platform rapidly engineers macrophages with switchable AI-peptides for personalized solid tumor therapy.
Disclaimer: Any opinions, findings, conclusions or recommendations expressed in this material/event (or by members of the project team) do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Innovation and Technology Commission or the General Support Programme Vetting Committee of the Innovation and Technology Fund.
© Designed by WHALE CASTLE IT CONSULTANT, Powered by MAGIC SQUARE STUDIO